In the Boardroom
Refine Search
Generics
Somewhat sooner than expected, Isael’s Teva Pharmaceutical Industries, the world’s largest generics drugmaker, has confirmed recent reports, saying that Erez Vigodman has been appointed president and chief executive, effective February 11. 9 January 2014
Biotechnology
Merck Serono, the biotech unit of Germany’s Merck KGaA (MRK: DE), has named Steven Hildemann as global chief medical officer and head of global medical and safety for the Merck Serono division. 9 January 2014
Biotechnology
US biotech company Promedior has announced that industry veteran William Hodder has joined the company as Vice President of Business Development. 8 January 2014
Pharmaceutical
US biopharmaceutical company Blend Therapeutics has appointed pharmaceutical industry veteran Richard Wooster as chief scientific officer. 7 January 2014
Generics
Speculation is mounting that Israel’s Teva Pharmaceutical Industries is about to appoint a new chief executive, after ousting 18-month incumbent of the post, Jeremy Levin, last October. 7 January 2014
Pharmaceutical
Canadian drugmaker AEterna Zentaris (TSX: AEZ) has appointed Richard Sachse as senior vice president, chief scientific officer. 4 January 2014
Generics
US drugmaker Mylan says that Rakesh Bamzai has joined the company and has been appointed president, India commercial and emerging markets. 4 January 2014
Biotechnology
US synthetic biology companies Agilis Biotherapeutics and Intrexon have entered an exclusive channel collaboration to develop DNA-based therapeutics for Friedreich's ataxia, a rare genetic neurodegenerative disease. 1 January 2014
Biotechnology
The supervisory board of German drugs and chemicals major Bayer (BAYN: DE) has appointed Kemal Malik to the Board of Management with the responsibility for innovation and taking over the North America region. 20 December 2013
Pharmaceutical
French pharmaceutical company Ipsen has announced the appointment of Dominique Brard as Executive Vice President in charge of Human Resources of the Ipsen group in place of Etienne de Blois. 19 December 2013
Pharmaceutical
Sydney-based companion diagnostic and personalized medicine company Clarity has appointed Alan Taylor as its new executive chairman to the board. 19 December 2013
Pharmaceutical
When it comes to being different, privately-owned Ferring Pharma is proud of its culture of enterprise driven by science, not profit. 18 December 2013
Pharmaceutical
Changes in Pfizer’s (NYSE: PFE) executive leadership have been announced this week. 18 December 2013
Biotechnology
German biotechnology company Lophius Biosciences GmbH has announced that Dr Robert Phelps has joined the company as director of business operations. 16 December 2013
Pharmaceutical
New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments to its executive leadership team. The appointments are part of Forest’s plans to broaden the organization as part of Project Rejuvenate. 16 December 2013
Pharmaceutical
Danish pharmaceutical company H. Lundbeck A/S has appointed Jacob Tolstrup as head of the HR department following the resignation of former HR vice president Teddy Hebo Larsen. 16 December 2013
Generics
Israel’s Teva Pharmaceutical Industries announced yesterday that the vice chairman of its board of directors, Moshe Many, has requested to leave his position effective January 1, 2014. Prof Many will remain a member of Teva's Board. 11 December 2013
Pharmaceutical
Swiss drug major Roche (ROG: SIX) has issued a list of members of the Board of Directors to be elected at its AGM on March 4, 2014. The board proposes Christoph Franz to be elected as Chairman of the Board. 10 December 2013
Pharmaceutical
Denmark-based small molecule lead discovery company Nuevolution A/S has appointed Ton Berkien as Chief Business Officer from January 1. 9 December 2013
Pharmaceutical
Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR: BR) has announced that Désiré Collen has decided to retire as chairman and board member. 9 December 2013
Biotechnology
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
Anthony Harnden has been appointed as the new chair of the UK’s Medicine and Healthcare products Regulatory Agency (MHRA). 20 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
Biotechnology
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
Pharmaceutical
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze